Barbara Burtness

Yale Cancer Center ORCID: 0000-0003-4660-1859

3

h-index

3

Publications

6,357

Citations

Publications

3 shown

Head and neck squamous cell carcinoma

Daniel E. Johnson , Barbara Burtness , C. René Leemans +3 more

2020 Nature Reviews Disease Primers 3577 citations

Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial

Tanguy Y. Seiwert , Barbara Burtness , Ranee Mehra +9 more

2016 The Lancet Oncology 1684 citations

Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial

Kei Muro , Hyun Cheol Chung , Veena Shankaran +15 more

2016 The Lancet Oncology 1096 citations

Frequent Co-Authors

Daniel E. Johnson

University of California, San Francisco

C. René Leemans

Vrije Universiteit Amsterdam

Vivian Wai Yan Lui

Chinese University of Hong Kong

Julie E. Bauman

University of Arizona

Jennifer R. Grandis

University of California, San Francisco

Tanguy Y. Seiwert

University of Chicago

Researcher Info

h-index: 3
Publications: 3
Citations: 6,357
Institution: Yale Cancer Center

External Links

ORCID Profile Google Scholar

Identifiers

ORCID: 0000-0003-4660-1859

Impact Metrics

h-index 3

h-index: Number of publications with at least h citations each.